Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 10/19
4641JPY
-1.34%
Prev.4704.0000
Open4612.0000
High4660.0000
Low4571.0000
Volume5 984 300
Financials
Sales 2019 1 765 B
EBIT 2019 -
R. net 2019 162 B
Debt 2019 680 B
Rend. 2019 3,88%
P/E ratio 2019 22,38
P/E ratio 2020 18,45
EV / Sales 2019 2,47x
EV / Sales 2020 2,33x
Capitalization 3 688 B
Company
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs.It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other.The Prescription Drugs segment includes the manufacture...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-10-31 Earnings Release
Trading Rating :
Investor Rating :
Latest news
10/19TAKEDA PHARMACEUTICAL : to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib)
PU
10/19TAKEDA PHARMACEUTICAL : to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
BU
10/18TAKEDA PHARMACEUTICAL : Japan’s Takeda gets regulator’s approval to acquire Shire Plc
AQ
10/18TAKEDA PHARMACEUTICAL : gets Japanese approval for $62 billion Shire purchase
RE
10/18TAKEDA PHARMACEUTICAL : Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
BU
10/18TAKEDA PHARMACEUTICAL : receives clearance from the Japan Fair Trade Commission for the proposed acquisition of Shire plc
PU
10/12TAKEDA PHARMACEUTICAL : Earnings Conference for the 2nd Quarter of Fiscal Year 2018
PU
10/06SHIRE : Disgruntled Takeda alumni demand a window into $62B Shire buy
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralNeutralBearish
Resistance4 9234 9235 349
Spread/Res.-5,7%-5,7%-13%
Spread/Supp.6,1%10%8,2%
Support4 3744 2034 290